ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2417

Influence of Histological Tempol Artery Biopsy Findings on Outcomes of Biopsy-proven Giant Cell Arteritis in Italian Patients : A Long Single Center Follow-up Study

LUIGI BOIARDI1, PIERLUIGI MACCHIONI2, Francesco Muratore3, Elena Galli4, chiara marvisi4, caterina Ricordi4, federica Macaluso1, alberto cavazza4, Stefania Croci4 and Carlo Salvarani5, 1IRCCS REGGIO EMILIA, Reggio Emilia, Italy, 2Azienda USL -IRCCS di Reggio Emilia, Reggio Emilia, Italy, 3IRCCS di Reggio Emilia, Reggio Emilia, Italy, 4Azienda Unità Sanitaria Locale-IRCCS Di Reggio Emilia, Reggio Emilia, Italy, 5Azienda USL-IRCCS di Reggio Emilia, Reggio Emilia, Italy

Meeting: ACR Convergence 2023

Keywords: Vasculitis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Tuesday, November 14, 2023

Title: (2387–2424) Vasculitis – Non-ANCA-Associated & Related Disorders Poster III

Session Type: Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose: Few studies have evaluted the influence of histological features of temporal artery biopsy (TAB) on disease outcome in giant cell arteritis (GCA) patients. Our aim was to investigate potential associations between TAB histological characterstics and outcomes of GCA in a long term single center retrospective follow-up study.

Methods: Two hundred and four Italian patients with biopsy-proven GCA resident in Reggio Emilia area (Italy) followed up for at least 12 months entered the study (median duration of FU 130 months(range 13-435 months). The following histological findings of TAB were recorded : localisation of inflammatory infiltrate (peri-adventitial and vasa vasorum small vessel vascultis (SVV+VVV), inflammation limited to adventitia (ILA), trans mural inflammation TMI), presence of giant cells (GC), presence of infiltrating neutrophils, plasma cells, histiocytes, eosinophils, presence of laminar necrosis (LN), vessel wall calcifications, luminal trombosis (LT) and intimal hyperplasia (IH). The severity of inflammation (SI) was graded on a semiquantitative scale (mild, moderate and severe), the severity of i IH (was graded as mild < 25% reduction in lumen diameter, moderate from 25% to 75%, and severe >75%).

The following data were recorded during follow up : presence of relapses, long term remission (LTR), cumulative steroid dose at 6, 12 months and at end of FU, duration of treatment and of LTR and mortality. Survival curve were compared with K-M method using log rank test.

Results: Relapses were recorded by 42.5% of the patients during a median FU period of 130 months (13-435). Factors which influenced the time of first relapse were : presence of GC (140 vs 207 months, p=0.025), presence of LT (91 vs 171 months, p=0.036) and histological subtype (80 vs 156 vs 249 months for SVV+VVV, ILA and TMI respectively, p=0.017). Fifty-seven % of patients were able to withdraw steroids for at least 12 month. Histological subtypes influenced the duration of treatment (SVV+VVV 2.7 months, ILA 17.9 months, TMI 32.0 months, p=0.019). Seventy % of patients died during the follow up period. Factors with impact on survival time were : SI severe vs mild infiltrate (107 months vs 155 months, p=0.006), presence of GC (112 vs 154 months, p=0.049), presence of LN (96 months vs 132 months, p=0.029), histological subtypes (TMI 115 months vs ILA 161 months vs SVV+VVV 195 months, p= 0.017).

Conclusion: Histological findings of TAB influenced survival time, first relapse time and duration of steroid treatment in GCA pts.


Disclosures: L. BOIARDI: None; P. MACCHIONI: None; F. Muratore: None; E. Galli: None; c. marvisi: None; c. Ricordi: None; f. Macaluso: None; a. cavazza: None; S. Croci: None; C. Salvarani: CSL Vifor, 1, 2, 6, Eli Lilly, 1, 2, 6.

To cite this abstract in AMA style:

BOIARDI L, MACCHIONI P, Muratore F, Galli E, marvisi c, Ricordi c, Macaluso f, cavazza a, Croci S, Salvarani C. Influence of Histological Tempol Artery Biopsy Findings on Outcomes of Biopsy-proven Giant Cell Arteritis in Italian Patients : A Long Single Center Follow-up Study [abstract]. Arthritis Rheumatol. 2023; 75 (suppl 9). https://acrabstracts.org/abstract/influence-of-histological-tempol-artery-biopsy-findings-on-outcomes-of-biopsy-proven-giant-cell-arteritis-in-italian-patients-a-long-single-center-follow-up-study/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2023

ACR Meeting Abstracts - https://acrabstracts.org/abstract/influence-of-histological-tempol-artery-biopsy-findings-on-outcomes-of-biopsy-proven-giant-cell-arteritis-in-italian-patients-a-long-single-center-follow-up-study/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology